Extrapelvic colon—areas of failure in a reoperation series: Implications for adjuvant therapy

Gunderson, Leonard L.; Sosin, Henry; Levitt, Seymour H.

doi:10.1016/0360-3016(85)90305-0

Cited by 132 publications

(32 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NCDB patients were treated by conventional surgical resection. 29 It appears that the incidence of wound recurrence after OPEN is probably low but still underestimated. 26 Furthermore, the rates of wound recurrence are influenced by several factors.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Survival After Laparoscopic Colon Resection for Cancer

Lujan

Plasencia

Jacobs

et al. 2002

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Survival After Laparoscopic Colon Resection for Cancer

Lujan

Plasencia

Jacobs

et al. 2002

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

“…Although adjuvant therapy has decreased the risk of pelvic relapse (2,3), the consequences of local relapse are devastating (4,5). Locoregional relapse of colon cancer occurs relatively frequently with tumor penetration through the bowel wall and regional lymph node involvement (6)(7)(8)(9)(10). Relapse in presacral or para-aortic lymph nodes is observed in patients with nodepositive disease.…”

Section: Introductionmentioning

confidence: 98%

Combined Modality Therapy Including Intraoperative Electron Irradiation for Locally Recurrent Colorectal Cancer

Haddock

Miller

Pembérton

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

Self Cite

118

View full text Add to dashboard Cite

“…Following curative resection for colon cancer metachronous peritoneal carcinomatosis is reported in 4% to 12% of patients in 2% to 19% of patients following curative resection for rectal cancer [19].…”

Section: Discussionmentioning

confidence: 99%

Avoidance of Early Post-Operative Intraperitoneal Chemotherapy (EPIC) Following Peritonectomy with Heated Intraperitoneal Chemotherapy (HIPEC) Significantly Reduces Cost and Hospital Stay

Kirby¹,

Zhao²,

Chua³

et al. 2014

TOSOJ

View full text Add to dashboard Cite

Abstract:Aims: Peritoneal carcinomatosis is treated with Cytoreductive surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC) with or without Early Postoperative Intraperitoneal Chemotherapy (EPIC) depending on the pathology involved. Since 2010 heated intraperitoneal oxaliplatin has been utilised in our institution. Our aim was to determine if there was a significant cost difference between patients receiving oxaliplatin and those requiring five additional days of EPIC. Methods:We retrospectively analysed 30 patients from our database. 15 patients underwent cytoreductive surgery, heated intraperitoneal oxaliplatin (350mg/m 2 ) and 5-fluorouracil (FU) intravenously administered intraoperatively. We compared those patients with 15 patients who underwent CRS, heated intraperitoneal mitomycin C (10-25mg/m 2 ) as well as EPIC with 5-FU (600-800mg/m 2 ) on postoperative days 1 to 5. Patients were matched for age, gender, pathology and peritoneal carcinomatosis index (PCI).Results: There was no significant difference between radiology (p=0.6) and transfusion costs (p=0.4). The chemotherapy costs in the oxaliplatin group were significantly higher (p=0.001) however overall bed costs including ward, HDU and ICU were significantly lower in the oxaliplatin group (p 0.029). There was a higher percentage of patients in the EPIC group that had postoperative ileus (p 0.4), rate of infection (p 0.1), fistula formation (p 0.03), return to theatre (p 0.2) and collection formation (p 0.07) compared to the oxaliplatin group. The overall cost was significantly lower in the oxaliplatin group (p 0.038). There was no significant survival benefit between both groups (p 0.3). Conclusion:In colorectal cancer the cost and complications of EPIC following HIPEC are unjustified. We now use oxaliplatin HIPEC as our standard regimen in colorectal cancer and appendiceal adenocarcinoma.

show abstract

Extrapelvic colon—areas of failure in a reoperation series: Implications for adjuvant therapy

Cited by 132 publications

References 29 publications

Long-Term Survival After Laparoscopic Colon Resection for Cancer

Long-Term Survival After Laparoscopic Colon Resection for Cancer

Combined Modality Therapy Including Intraoperative Electron Irradiation for Locally Recurrent Colorectal Cancer

Avoidance of Early Post-Operative Intraperitoneal Chemotherapy (EPIC) Following Peritonectomy with Heated Intraperitoneal Chemotherapy (HIPEC) Significantly Reduces Cost and Hospital Stay

Contact Info

Product

Resources

About